By Tarun Sai LomteMay 13 2024Reviewed by Susha Cheriyedath, M.Sc. In a recent study published in the International Journal of Obesity , researchers investigated the effects of combined glucagon-like peptide 1 analog and bupropion/naltrexone treatment on weight loss .
GLP-1 inhibits agouti-related peptide and hypothalamic neuropeptide Y for homeostatic appetite regulation, reducing hunger, and increasing satiety. A trial reported that a 1-mg weekly dose of semaglutide was associated with 6 kg weight loss in diabetes patients. Bupropion inhibits noradrenaline and dopamine reuptake, whereas naltrexone is an opioid antagonist of the mesolimbic reward pathway, reducing rewards/pleasure-based or hedonic hunger.
Individuals who received bupropion/naltrexone before GLP-1 analog therapy and those with surgical treatment for obesity before or during the study were excluded. Participants received lifestyle recommendations through counseling sessions or educational materials. Data on the use and dosage of GLP-1 analogs, bupropion, and naltrexone were collected.
Findings Overall, 415 participants were included for analysis. Over three-fourths of subjects were female; most individuals had a BMI ≥ 40 kg/m2. Participants were followed up for approximately 511 days, on average. All subjects were started on GLP-1 analog monotherapy, and 22.9% were initiated on the add-on treatment . Comorbidities were similar between patients on GLP-1 analog monotherapy and combination therapy.
GLP-1 Naltrexone Weight Loss Cancer Diabetes Diet Exercise Glucagon Obesity Osteoarthritis Research
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: wallpapermag - 🏆 36. / 67 Read more »
Source: eurogamer - 🏆 68. / 61 Read more »
Source: NewsMedical - 🏆 19. / 71 Read more »
Source: LeedsNews - 🏆 48. / 63 Read more »
Source: medical_xpress - 🏆 101. / 51 Read more »
Source: medical_xpress - 🏆 101. / 51 Read more »